Vorinostat (Figure 5) is a class I/IIb/IV HDAC inhibitor, FDA approved for the treatment of cutaneous T-cell lymphoma (CTCL) and identified to be a potent inhibitor of HIF-1 signaling. The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.